| Autor: |
Cho I; Department of Dermatology.; Black Family Stem Cell Institute., Ji AL; Department of Dermatology.; Black Family Stem Cell Institute.; Department of Oncological Sciences.; Department of Cell, Developmental and Regenerative Biology, and.; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
The Journal of clinical investigation [J Clin Invest] 2024 Sep 03; Vol. 134 (17). Date of Electronic Publication: 2024 Sep 03. |
| DOI: |
10.1172/JCI183708 |
| Abstrakt: |
Sarcoidosis is an inflammatory disease characterized by immune cell-rich granulomas that form in multiple organs. In this issue of the JCI, Sati and colleagues used scRNA-seq and spatial transcriptomics of skin samples from patients with sarcoidosis and non-sarcoidosis granulomatous disease to identify upregulation of a stromal-immune CXCL12/CXCR4 axis and accumulation of type 1 innate lymphoid cells (ILC1s) in sarcoidosis. The accumulation of ILC1s in skin and blood was specific to patients with sarcoidosis and not observed in other granulomatous diseases. The authors used a mouse model of lung granuloma to show that ILCs contribute to granuloma formation and that blockade of CXCR4 reduced the formation of granulomas, providing a proof of concept that sarcoidosis may be treated by CXCR4 blockade to prevent the progression of disease in patients. These results suggest ILC1s could serve as a diagnostic biomarker in sarcoidosis and a potential therapeutic target. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
